Peptide ID (location) | Sera infected with one serotype | Sera infected with two serotypes | |||
---|---|---|---|---|---|
DENV1 serotype | DENV2 serotype | DENV3 serotype | DENV4 serotype | ||
P1/E (7–23) | 1 8% | 0 0% | 0 0% | 1 8% | 0 0% |
P2/E (30–46) | 12 100% | 9 75% | 6 50% | 0 0% | 4 33% |
P3/E (60–76) | 10 83% | 0 0% | 9 75% | 12 100% | 5 42% |
P4/E (72–88) | 12 100% | 12 100% | 12 100% | 12 100% | 11 91% |
P5/E (89–104) | 12 100% | 12 100% | 12 100% | 12 100% | 10 83% |
P6/E (110–126) | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% |
P7/E (178–194) | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% |
P8/E (238–254) | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% |
P9/E (255–271) | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% |
P10/E (279–295) | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% |
P11/E (308–324) | 6 50% | 0 0% | 5 42% | 0 0% | 0 0% |
P12/E (371–387) | 9 75% | 1 8% | 9 75% | 0 0% | 2 17% |
P13/E (377–393) | 0 0% | 12 100% | 9 75% | 9 75% | 6 50% |
P14/E (394–410) | 10 83% | 10 83% | 12 100% | 12 100% | 12 100% |
P15/E (418–434) | 12 100% | 12 100% | 12 100% | 12 100% | 12 100% |
P16/E (424–440) | 0 0% | 12 100% | 10 83% | 10 83% | 5 42% |
P17/E (458–474) | 10 83% | 9 75% | 9 75% | 9 75% | 8 67% |